Business Wire

lululemon and the United Nations Foundation Launch New Program to Address Mental and Physical Health of UN Humanitarian Aid Workers

Share

lululemon and the United Nations Foundation today announced their partnership around an innovative program to address the mental and physical health of UN development and humanitarian workers who serve on the front lines of urgent global challenges, so they can better support communities around the world. lululemon will commit $1 million USD over the next three years to Peace on Purpose, an evidence-based program, which provides access to mindfulness and self-care tools and resources for UN workers to build resilience in the face of adversity and stressful environments – such as responding to humanitarian emergencies, supporting communities facing poverty, and more. Peace on Purpose's mission is to equip aid workers with the tools to care for themselves so they can effectively care for others.

“lululemon and the UN Foundation share a commitment to building community and developing collaborative solutions for some of the world’s most pressing issues,” said Calvin McDonald, CEO of lululemon. “With increasing need for international humanitarian aid and peacekeeping, we want to cultivate the long-lasting benefits of mindfulness tools and sustain support for those whose mission is to serve others.”

“UN workers are on the front lines of global challenges, helping people in their times of greatest need,” said Kathy Calvin, President and CEO of the UN Foundation. “This work can often be stressful, and the UN has made it a priority to address the well-being of its people. Innovative partnerships like Peace on Purpose can support the UN workers who support the world. With lululemon’s support, we will be able to grow the program to help more UN staff care for themselves and for others.”

Peace on Purpose is a result of a three-year pilot led by lululemon’s Here to Be team and the UN Foundation, developed to address a series of issues, such as burnout, compassion fatigue, and stress-related physical, mental, and relational effects reported by UN staff members. Peace on Purpose has worked with UN agencies to build out trainings and workshops for more than 650 staff in US headquarters and seven additional countries – Jordan, Lebanon, Pakistan, South Sudan, Turkey, Turkmenistan and Zimbabwe.

Research that followed select trainings found that over half of the participants experienced a more than 40 percent improvement in overall well-being as seen in key psychological risk factors, such as work-related self-compassion, anxiety and depression, symptoms related to trauma, and feelings of distress.

Humanitarian aid workers report experiencing high rates of burnout, stress, and mental health stigmas in difficult global settings. Peace on Purpose’s curriculum introduces mindfulness tools as well-being resources to support current UN mental health programs. These tools – such as mindful breaths, emotion regulation, and yoga – can be implemented to meet the varying needs of UN staff in the diverse environments in which they operate.

With lululemon’s continued funding commitment and thought partnership, Peace on Purpose will aim to train 3,000 more UN development and humanitarian workers in-person over the next three years, build a hub of digital resources, and develop condensed trainings and curriculum translations to reach an additional 30,000 UN staff.

Peace on Purpose is a key element of lululemon’s commitment to social impact and sustainability. The company’s Impact Agenda is comprised of three elements – Be Human, Be Well and Be Planet – to support and accelerate meaningful positive impact around the world.

To learn more about Peace on Purpose or lululemon’s Global Impact Agenda, including Here to Be, visit https://shop.lululemon.com/story/sustainability.

About lululemon athletica inc.
lululemon athletica inc. (NASDAQ:LULU) is a healthy lifestyle inspired athletic apparel company for yoga, running, training, and most other sweaty pursuits, creating transformational products and experiences which enable people to live a life they love. Setting the bar in technical fabrics and functional designs, lululemon works with yogis and athletes in local communities for continuous research and product feedback. For more information, visit www.lululemon.com.

About the United Nations Foundation
The United Nations Foundation acts as a strategic partner to help the United Nations mobilize the ideas, people, and resources it needs to drive global progress and tackle urgent challenges. We focus on issues at the heart of the Sustainable Development Goals, build initiatives across sectors to solve problems at scale, and engage citizens who seek action. Founded in 1998 by entrepreneur and philanthropist Ted Turner, the UN Foundation works with philanthropic, corporate, government, and individual partners. Learn more at www.unfoundation.org.

Contact information

Media:
lululemon
Tatiana Jovic
Director, Global PR
media@lululemon.com

Sunshine Sachs PR
lululemon@sunshinesachs.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing